AI Drug Discovery Business Plan

Executive Summary

The Company

AI Drug Discovery, Partership, provides computer software and software as service (SaaS) training services, primarily to the pharmaceutical and academic market. The firm will deliver on premises training to corporations. We hope to offer online versions of our courses that can be accessed from anywhere as well as guides and e-books. We would like to create a partner network for our customers to share their models and the data they created with the software to increase their business. The goal is to perform analyses for our pharmaceutical customers providing value by predicting the best compounds and designing libraries. We will also create custom algorithms for customers with long term contracts. The AI/pharmaceutical contracting niche has 200 million dollars in revenue in the United States, and AI Drug Discovery hopes to capitalize on its growth. The company’s stock will be held by CEO Colin Kruse, Patrick Chirdon CTO, Dr.Sumit Sharma, and Dr.Douglas Goetz (advisors).

Products and Services

We will will license out our base toolkit created with Ohio University through the tech transfer office. We will also provide on site training and installation of our software. We will screen compounds on a contractual basis, create machine learning models, and screen for toxicity and other properties. We hope to expand our services by building algorithms for absorption, distribution, metabolism, and excretion etc. We also hope to publish and assist in clinical…